Table 3.
Adverse Event | Grade |
P | |||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
CIS Plus RT (n = 187) |
CIS, TPZ, and RT (n = 179) |
||||||||||
0 | 1 | 2 | 3 | 4 | 0 | 1 | 2 | 3 | 4 | ||
Leukopenia | 48 | 30 | 60 | 43 | 6 | 53 | 26 | 47 | 47 | 6 | |
Anemia | 37 | 60 | 75 | 16 | 0 | 46 | 58 | 65 | 10 | 0 | |
Thrombocytopenia | 115 | 57 | 8 | 5 | 2 | 113 | 52 | 8 | 3 | 3 | |
ANC | 103 | 25 | 31 | 20 | 8 | 101 | 22 | 30 | 23 | 3 | |
Other hematologic | 163 | 2 | 3 | 11 | 8 | 160 | 2 | 1 | 9 | 7 | |
Allergy/immunology | 182 | 4 | 1 | 0 | 0 | 171 | 4 | 2 | 2 | 0 | |
Auditory/ear | 161 | 2 | 11 | 0 | 0 | 68 | 0 | 19 | 0 | 1 | |
Cardiac | 179 | 5 | 2 | 1 | 0 | 152 | 1 | 25 | 0 | 0 | |
Fatigue | 49 | 66 | 58 | 14 | 0 | 49 | 61 | 46 | 20 | 3 | |
Fever, without neutropenia | 176 | 8 | 3 | 0 | 0 | 171 | 3 | 5 | 0 | 0 | |
Other constitutional symptoms | 139 | 38 | 10 | 0 | 0 | 120 | 39 | 18 | 2 | 0 | |
Dermatologic* | 137 | 36 | 14 | 0 | 0 | 102 | 35 | 26 | 15 | 1 | < .001 |
Endocrine | 174 | 8 | 4 | 1 | 0 | 175 | 3 | 1 | 0 | 0 | |
Nausea | 60 | 77 | 37 | 13 | 0 | 46 | 63 | 58 | 12 | 0 | |
Vomiting* | 113 | 41 | 21 | 12 | 0 | 74 | 44 | 49 | 12 | 0 | < .001 |
Diarrhea* | 72 | 81 | 23 | 11 | 0 | 70 | 52 | 38 | 19 | 0 | .007 |
Constipation | 149 | 29 | 9 | 0 | 0 | 143 | 23 | 11 | 1 | 1 | |
Other GI | 108 | 43 | 28 | 8 | 0 | 91 | 38 | 41 | 8 | 1 | |
Renal/genitourinary | 135 | 30 | 20 | 2 | 0 | 142 | 26 | 9 | 2 | 0 | |
Hemorrhage/bleeding | 169 | 16 | 1 | 1 | 0 | 165 | 10 | 2 | 2 | 0 | |
Hepatobiliary/pancreas | 187 | 0 | 0 | 0 | 0 | 178 | 0 | 0 | 1 | 0 | |
Infection | 166 | 0 | 9 | 11 | 1 | 153 | 0 | 17 | 8 | 1 | |
Lymphatics | 181 | 6 | 0 | 0 | 0 | 164 | 10 | 4 | 1 | 0 | |
Metabolic/laboratory | 92 | 45 | 25 | 19 | 6 | 76 | 47 | 19 | 33 | 4 | |
Musculoskeletal/soft tissue | 176 | 7 | 4 | 0 | 0 | 159 | 8 | 7 | 5 | 0 | |
Neuropathy, motor* | 186 | 0 | 1 | 0 | 0 | 168 | 6 | 5 | 0 | 0 | .003 |
Neuropathy, sensory | 159 | 24 | 3 | 1 | 0 | 152 | 20 | 6 | 1 | 0 | |
Other neurologic | 157 | 20 | 8 | 1 | 1 | 137 | 25 | 9 | 8 | 0 | |
Ocular/visual | 179 | 8 | 0 | 0 | 0 | 163 | 15 | 1 | 0 | 0 | |
Pain* | 118 | 42 | 24 | 3 | 0 | 76 | 36 | 38 | 29 | 0 | < .001 |
Pulmonary | 174 | 10 | 1 | 2 | 0 | 164 | 8 | 3 | 4 | 0 | |
Sexual/reproductive | 168 | 18 | 1 | 0 | 0 | 166 | 9 | 4 | 0 | 0 | |
Vascular | 182 | 2 | 0 | 3 | 0 | 175 | 0 | 1 | 2 | 1 |
NOTE. There was one treatment-related death.
Abbreviations: ANC, absolute neutrophil count; CIS, cisplatin; RT, radiotherapy; TPZ, tirapazamine.
Distribution of toxicity grade significantly different across treatment arms (Fisher's exact test).